期刊文献+

晚期糖基化终末产物受体与核因子-κβ在中耳胆脂瘤中的表达 被引量:5

Expression of receptors for advanced glycation end product(RAGE) and nuclear factor-κβ(NF-κβ) in middle ear cholesteatoma
在线阅读 下载PDF
导出
摘要 目的研究中耳胆脂瘤中核因子-κβ(NF-κβ)与晚期糖基化终末产物受体(RAGE)的表达,探究上皮炎症反应在胆脂瘤的发病机制中的作用,寻找可能的中耳胆脂瘤干预治疗措施。方法中耳胆脂瘤手术中收集中耳胆脂瘤标本23例及正常外耳道皮肤组织18例,采用免疫组化法检验两种标本中NF-κβ和RAGE表达分布。结果胆脂瘤上皮组织中NF-κβ表达强度显著高于正常外耳道皮肤组织,两者NF-κβ阳性平均光密度分别为0.442±0.060及0.293±0.047(t=8.654,P<0.01);胆脂瘤上皮组织中RAGE表达强度显著高于正常外耳道皮肤组织,两者RAGE阳性平均光密度分别0.175±0.017及0.133±0.013(t=8.516,p<0.01)。胆脂瘤上皮NF-κβ与RAGE表达具有弱相关性r=0.546(P=0.034)。结论 NF-κβ与RAGE在中耳胆脂瘤上皮中表达增加,可能在胆脂瘤的发生和持续发展中起重要作用。调控NF-κβ与RAGE信号传导通路可能是中耳胆脂瘤治疗干预的有效靶点之一。 Objective To study the roles of NF-Kβ and RAGE in the pathogenesis of middle ear cholesteatoma. Methods Samples of middle ear cholesteatoma (n=23) and normal external ear canal skin (n=l 8) were collected during middle ear surgeries. Expression of NF-Kβ and RAGE was examined by immunohistochemistry. Results All epithelial cells in cholesteatoma revealed abundant plasma expression of NF-Kβ and RAGE, significantly higher than that in normal skin (0.442±0.060 vs 0.293±0.047 and 0.175±0.017 vs 0.133±0.013, respectively; p〈0.01). There was a weak correlation between NF-Kβ and RAGE expression in middle ear cholesteatoma epithelium tissues (r=0.546, p=0.034). Conclusion NF-kβ and RAGE may be important factors involved in the occurrence and development of middle ear cholesteatom. The signal pathway of RAGE and NF-Kβ may be a new drug target in non-surgical treatment of middle ear cholesteatoma.
作者 廖军 林昶
出处 《中华耳科学杂志》 CSCD 北大核心 2015年第4期729-733,共5页 Chinese Journal of Otology
基金 泉州市社会发展科技计划项目(2013Z60) 泉州市卫生局资助
关键词 中耳胆脂瘤 核因子-κβ 晚期糖基化终末产物受体 middle ear cholesteatoma NF-kβ RAGE
  • 相关文献

参考文献27

  • 1Albino AP,Kimmelman CP,Parisier SC.Cholesteatoma:amolecular and cellular puzzle Am JO to,l 1998,19:7-191.
  • 2林刃舆,迟放鲁.中耳胆脂瘤形成机理的研究进展[J].国外医学(耳鼻咽喉科学分册),2001,25(3):153-156. 被引量:17
  • 3Haslbeck K M Schleicher E Bierhaus A et al.The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance(IGT)[J].Exp Clin Endocrinol Diabetes,2005,113(5):288-91.
  • 4Karin M,Greten FR.NF-kappa B:linking infamation and immunity to canncer devlopment and progressioon[J].Nat Rev Immunol,2005,5(10):749-549.
  • 5Tak PP,Firestein GS.NF-κB:a key role in inflammatory diseases.JClin Invest 2001;107:7-11.
  • 6Ghosh S,May MJ,Kopp EB.NF-κB and Rel proteins:evolu-tionarily conserved mediators of immune responses.Annu Rev Immunol1998;16:225-260.
  • 7Greten FR,Weber CK,Greten TF,Schneider G,Wagner M,Adler G,Schmid RM.Stat3 and NF-kappa B activation pre-vents apoptosis in pancreatic carcinogenesis.Gastroenterology 2002,123:2052-2063.
  • 8Stem DM,Yan SD,Yan SF,et al.Receptor for advaneced glyea-tion end products(RAGE)And the complications of diabetes.Ageing Res Rev,2002,1(1):1-15 Review.
  • 9Kim JY,Park HK,Yoon JS,et al.Advanced glycation end product(AGE)-induced proliferation of HEL cells via receptor for AGE-related signal pathways.Int J Oncol.2008 Sep;33(3):493-501.
  • 10Haslbeck K M Schleicher E Bierhaus A et al.The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance(IGT)[J].Exp Clin Endocrinol Diabetes,2005,113(5): 288-91.

二级参考文献40

  • 1Huang TT, Kudo N, Yoshida M, et al. A nuclear exprot signal in the Nterminal regulatory domain of IκBα controls cytoplasmic localization of inactive NF-κB/IκBα complexes[J]. Proc Natl Acad Sci, 2000, 97 (3):1014-1019.
  • 2Malek S, Chen Y, Huxford T, et al. IκBβ, but not IκBα, functions as a classical cytoplasmic inhibitor of NF-κB dimers by masking both NF-κB nuclear localizationsequences in resting cells[J] .J Biol Chem,2001,276(48):45225-45235.
  • 3Imler JL, Hoffmann JA. Toll and Toll-like proteins: an ancient family of receptors signaling infection[ J ]. Rev Immunogenet, 2000,2(7): 294-304.
  • 4Sivakumar V, Hammond K J, Howells N, et al. Differential requirement for Rel/nuclear factor kappa B family members innatural killer T cell development[J] .J Exp Med,2003,197(12): 1613-1621.
  • 5Green DB. Death and NF-kappaB in T cell activation: life at the edge [J]. Mol Cell,2003,11 (3) :551-552.
  • 6Vandenbroeck K, Alloza I, Gadina M, et al. Inhibiting cytokines of the interleukin-12 family: recent advances and novelchallenges[J]. J Pharm Pharmacol, 2004,56(2): 145-160.
  • 7Li-Weber M, Giaisi M, Baumann S, et al. NF-kappa B synergizes with NF-AT and NF-IL6 in activation of the IL-4 gene in T cells[J]. Eur J Immunol, 2004, 34(4): 1111-1118.
  • 8Yoshimura S, Bondeson J, Brennan FM, et al. Antigen presentation by murine dendritic cells is nuclear factor-kappa B dependent both in vitro and in vivo[J]. Scand J Immunol,2003,58(2) :165-172.
  • 9Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity[J] .Annu Rev Immunol,2000,18:621-663.
  • 10Silverman N, Maniatis T. NF-κB signaling pathways inmammalian and insect innate immunity[J]. Genes Dev,2001,15(18):2321-2342.

共引文献21

同被引文献42

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部